Get started

Get connected with your Myriad Account Executive to learn how Prolaris is personalizing prostate cancer care.

Get connected with your Myriad Account Executive to learn how Prolaris is personalizing prostate cancer care.

Hidden Fields

You agree to be contacted with newsletters, marketing or promotional materials and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in any email we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Policy.

One of these men is safe for active surveillance. The other only looks like he is.

It’s every urologist’s worst fear:

A prostate cancer patient appeared safe for Active Surveillance at diagnosis based on clinical and pathological features like Gleason and PSA. But after just a year on AS, this patient’s PSA is much higher and he has hip pain.

Why did this seemingly low-risk patient progress so drastically? Because there’s variability and subjectivity within pathology.

Clin-path alone doesn’t provide the whole picture, which is what every man wants, and what you need to make the most informed treatment decisions possible.

Now there’s a much better way of determining the true aggressiveness of cancer. Prolaris is a powerful tool that combines personalized information of tumor behavior with traditional clinician-path features to create the most prognostic information available. The Prolaris test offers unparalleled utility and unbiased insights to help you confidently recommend the best course of treatment for your patients. Which man is safe for AS? You can’t pick him out without Prolaris.

plays UroSuite provider videolightbox

Testing can significantly alter recommended treatment for improved patient outcomes. Watch this video to learn more.

What is Prolaris?

Prolaris report example image

Prolaris is a prognostic, tumor-based biomarker test that looks at cell cycle proliferation (CCP) genes to determine the tumor’s behavior and assess prostate cancer aggressiveness.

While pathology offers a snapshot of how your patient’s cancer looks today, it doesn’t give you the full picture. Prolaris is more like a movie, combining both clin-path and genomics to tell—and show–what the cancer is doing, how it’s behaving, and potential outcomes from that behavior. Results are delivered in a comprehensive, easy-to-understand report, making it a useful tool to share with patients and help personalize patient care.

Testimonial from Ashleigh Renitsky, Oncology PA

"The presentation and the layout of the Prolaris report has absolutely changed the way that I speak to my patients in giving biopsy results. One of the first things I do when I walk into the room is pull that up and put it on the screen and we look at it together."

— Ashleigh Renitsky, Oncology PA

Prolaris helps you pinpoint the right treatment plan

When it comes to treating prostate cancer, precision matters. So does quality of life. You want to ensure that your patients aren’t undertreated or overtreated. Prolaris provides the backup you need while giving patients confidence that the treatment you recommend is the best path for them.

Active surveillance, a single form of treatment, or multiple forms of treatment? When making targeted treatment recommendations for your patients, don’t leave anything up to chance. Find out for sure with Prolaris.

The Prolaris Advantage

Prolaris is

  • The ONLY biomarker that offers unique insight into the speed at which the patient’s cancer is growing by focusing on CCP. 
  • The ONLY test that can tell you which patients would have little to no benefit from ADT.
  • The ONLY biomarker with an Active Surveillance threshold that was validated in untreated patients. 
  • The ONLY biomarker with two clinically validated thresholds.
  • The ONLY biomarker with a multi-modal threshold that was developed and double validated to predict the risk of metastasis and identify men who may have little to no benefit from multi-modal therapy.

What’s more, biomarker tests like Prolaris are supported by NCCN guidelines as a 2A recommendation which are all considered standard of care.

2X more

predictive than Gleason and PSA combined3

10K patients

have been validated across all risk groups with Prolaris4

Up to 65% change in treatment

In two clinical utility studies, Prolaris results lead to change in management in up to 65% of patients5-7

62% increase in AS population

Prolaris extends Active Surveillance candidate population by 62% compared to clinical and pathologic features alone5-7

97% of patients pay $0 out of pocket

Medicare covers at 100%. Average out of pocket is <$60. Financial assistance available

The standard of care that saves lives AND time

As a successful urologist, you’re in demand and time is in short supply.

With Prolaris, you’ll save precious time and move your prostate cancer patients toward the right type of treatment from the beginning. Because the Prolaris test is done at the time of diagnosis and requires no additional biopsy, results can be available at your patient’s first cancer consult. You’ll have all the clinical data plus cutting-edge genomic insights so you can make strong, clinically-validated treatment recommendations every time. We can even rush test results to your office if you need to develop a treatment plan immediately. In all cases, Prolaris should be performed before a patient has received any treatment.

Basic and streamlined ordering process imageBasic vs streamlined ordering process
Testimonial from Dr. Angelo Baccala, Urologist

"Pathology is important but we need to take another step because pathology is variable. Using Prolaris really helps us make personalized decisions for our patients."

— Dr. Angelo Baccala, Urologist

Be the hero

Your patients trust you with their lives and the treatment options you recommend can drastically improve their quality of life. You want to make sure to achieve the best possible clinical outcomes, and help your patients continue enjoying their retirement and family time. Don’t miss the opportunity to make the most informed decisions about their treatment.

  1. Schreiber D, Wong AT, Rineer J, Weedon J, Schwartz D. Prostate biopsy concordance in a large population-based sample: a Surveillance, Epidemiology and End Results study. J Clin Pathol. 2015 Jun;68(6):453-7. doi: 10.1136/jclinpath-2014-202767. Epub 2015 Mar 11. Erratum in: J Clin Pathol. 2015 Jul;68(7):e2. PMID: 25762729.
  2. Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol. 2001 Jan;32(1):74-80. doi: 10.1053/hupa.2001.21134. PMID: 11172298.
  3. Cuzick J, et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012;106:1095 -1099.
  5. Crawford ED, Scholz MC, Kar AJ, et al. Cell Cycle Progression Score and Treatment Decisions in Prostate Cancer:Results From an Ongoing Registry. Curr Med Res Opin 2014; 1-7
  6. Shore, N D., et al. Impact of the cell cycle progression test of physician and patient treatment selection for localized prostate cancer. The Journal of Urology 2016;195(3),612- 618
  7. Lin, D. W., et al. Identification of men with low-risk biopsy-confirmed prostate cancer as candidates for active surveillance. Urologic Oncology: Seminars and Original Investigations. 2018; doi: 10.1016/j.urolonc.2018.03.011.